title: Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
abstract: OBJECTIVE
  Intravenous iron therapy is an accepted treatment for patients receiving hemodialysis and continuous ambulatory peritoneal dialysis (CAPD). Studies have found enhanced oxidative stress in hemodialysis patients receiving intravenous iron, but there are no clinical data for CAPD patients. The aim of the current study was to investigate the effect of 100 mg of intravenous iron-sucrose on the erythrocyte (RBC) antioxidant enzymes (namely, superoxide dismutase [SOD], catalase [CAT], and glutathione peroxidase [GSHPx]) and plasma malondialdehyde (MDA), an oxidant molecule, in CAPD patients.
  
  
  METHODS
  Twelve CAPD patients receiving maintenance intravenous iron-sucrose were recruited. After a 12-hour fast, blood samples were taken for hemoglobin, iron, ferritin, and high-sensitivity C-reactive protein (hsCRP), and for baseline activities of erythrocyte antioxidant enzymes (i.e., SOD, CAT, GSHPx) and the plasma oxidant molecule, MDA. 100 mg iron-sucrose was infused over 30 minutes. Blood samples taken during (i.e., 15 minutes after commencement of infusion) and after (i.e., at 30 minutes, 60 minutes, and 6 hours after commencement) the infusion were taken for measurement of plasma iron, ferritin, TSAT, RBC SOD, CAT, GSHPx, and plasma MDA.
  
  
  RESULTS
  Plasma iron and transferrin saturation elevated significantly during infusion (p < 0.05). There was no significant change in erythrocyte SOD, CAT, GSHPx, or in MDA activities. There was a reduction of GSHPx activity at the 30th minute (from 153.69 +/- 66.69 to 123.68 +/- 25.50 mU/mL), but it was not statistically significant. The patients were grouped according to baseline ferritin (100-400 and 400-800 ng/mL); 60th-minute MDA was significantly higher in the latter group (p < 0.05). There was no correlation between hsCRP and oxidant-antioxidant balance. No correlation was noted between RBC antioxidant enzymes or plasma oxidant molecule and ferritin levels.
  
  
  CONCLUSIONS
  There are no acute deteriorating effects from a 100 mg of intravenous iron-sucrose in CAPD patients with optimal iron stores. This dose may be applied safely in CAPD patients.
authors.affiliation: Department of Nephrology, Dokuz Eylul University, School of Medicine, Izmir, Turkey.
authors.forename: Funda
authors.initials: F
authors.lastname: Saglam
authors.forename: Caner
authors.initials: C
authors.lastname: Cavdar
authors.forename: Sezer
authors.initials: S
authors.lastname: Uysal
authors.forename: Zahide
authors.initials: Z
authors.lastname: Cavdar
authors.forename: Taner
authors.initials: T
authors.lastname: Camsari
mesh_terms: D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D005979:Glutathione Peroxidase / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress; D010531:Peritoneal Dialysis, Continuous Ambulatory; D013395:Sucrose / Q000008:administration & dosage*
chemical_list: D005290:Ferric Compounds; D008315:Malondialdehyde; D013395:Sucrose; D002097:C-Reactive Protein; D005979:Glutathione Peroxidase; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid